Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

被引:2575
作者
Wan, PTC
Garnett, MJ
Roe, SM
Lee, S
Niculescu-Duvaz, D
Good, VM
Jones, CM
Marshall, CJ
Springer, CJ
Barford, D
Marais, R
机构
[1] Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, London SW3 6JB, England
[2] Inst Canc Res, Sect Struct Biol, London SW3 6JB, England
[3] Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, London SW3 6JB, England
[4] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England
[5] Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton, England
基金
英国惠康基金;
关键词
D O I
10.1016/S0092-8674(04)00215-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Over 30 mutations of the B-RAF gene associated with human cancers have been identified, the majority of which are located within the kinase domain. Here we show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo. Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells. The structures of wild type and oncogenic (VB)-B-599E-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by association with the P loop. The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation. The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.
引用
收藏
页码:855 / 867
页数:13
相关论文
共 48 条
[1]
Ras activation of the Raf kinase: Tyrosine kinase recruitment of the MAP kinase cascade [J].
Avruch, J ;
Khokhlatchev, A ;
Kyriakis, JM ;
Luo, ZJ ;
Tzivion, G ;
Vavvas, D ;
Zhang, XF .
RECENT PROGRESS IN HORMONE RESEARCH, VOL 56, 2001, 56 :127-155
[2]
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL [J].
Azam, M ;
Latek, RR ;
Daley, GQ .
CELL, 2003, 112 (06) :831-843
[3]
A scaleable synthesis of BAY 43-9006: A potent Raf kinase inhibitor for the treatment of cancer [J].
Bankston, D ;
Dumas, J ;
Natero, R ;
Riedl, B ;
Monahan, MK ;
Sibley, R .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2002, 6 (06) :777-781
[4]
Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs [J].
Blagosklonny, MV .
LEUKEMIA, 2002, 16 (04) :455-462
[5]
Brose MS, 2002, CANCER RES, V62, P6997
[6]
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[7]
*CCP4, 1991, ACTA CRYSTALLOGR D, V50, P760
[8]
Positive and negative regulation of Raf kinase activity and function by phosphorylation [J].
Chong, H ;
Lee, J ;
Guan, KL .
EMBO JOURNAL, 2001, 20 (14) :3716-3727
[9]
Lack of BRAF mutation in primary uveal melanoma [J].
Cohen, Y ;
Goldenberg-Cohen, N ;
Parrella, P ;
Chowers, I ;
Merbs, SL ;
Pe'er, J ;
Sidransky, D .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (07) :2876-2878
[10]
Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954